In the following video, Fool contributor Maxx Chatsko reviews the biggest catalysts for Regeneron's (REGN 0.20%) recent climb and near-rendezvous with $300 per share. The emerging biotech powerhouse has treated investors well in recent years -- returning more than 1,200% since 2008. While the company no doubt has a promising future, investors may be curious if things are getting too hot too fast. Did investors overreact to prior developments this year? Are shares priced for perfection? Or is $300 per share a benchmark that is actually within reach? The key lies in the pipeline.
Can This Biotech Roar Past $300?
By Maxx Chatsko – May 30, 2013 at 11:00AM
NASDAQ: REGN
Regeneron Pharmaceuticals
Market Cap
$73B
Today's Change
(-0.20%) $1.39
Current Price
$693.60
Price as of November 14, 2025 at 3:58 PM ET
A Fool outlines a way for Regeneron to eclipse the $300-per-share watermark.
About the Author
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.